What Is GLP-1? The Gut Hormone Behind Ozempic, Wegovy, and Modern Weight-Loss Medicine

Key Takeaways

• GLP-1, or glucagon-like peptide-1, is a hormone released by the small intestine after you eat.
• It tells the pancreas to release insulin, signals the brain that you're full, and slows the stomach so food stays longer.
• Drugs called GLP-1 receptor agonists copy this hormone for diabetes and weight loss.
• GLP-1 is one of two main "incretin" hormones, the other being GIP (glucose-dependent insulinotropic polypeptide).
• Both are released by L-cells in the lining of the small intestine within minutes of eating.

Direct answer (40-60 words, snippet-optimized)

GLP-1, or glucagon-like peptide-1, is a hormone released by the small intestine after you eat. It tells the pancreas to release insulin, signals the brain that you're full, and slows the stomach so food stays longer. Drugs called GLP-1 receptor agonists copy this hormone for diabetes and weight loss.

Table of contents

1. The 30-second answer
2. What GLP-1 actually does in the body
3. The discovery: from Gila monster venom to a $50 billion drug class
4. How GLP-1 medications differ from the natural hormone
5. The full list of GLP-1 drugs on the market
6. What GLP-1 medications treat (and what they don't)
7. The clinical data: how much weight, how much A1C
8. Side effects and the mechanism behind them
9. Who shouldn't take a GLP-1
10. Compounded vs brand-name GLP-1: a real comparison
11. What happens when you stop
12. FAQ
13. Footer disclaimers

What GLP-1 actually does in the body

GLP-1 is one of two main "incretin" hormones, the other being GIP (glucose-dependent insulinotropic polypeptide). Both are released by L-cells in the lining of the small intestine within minutes of eating. Native GLP-1 has a half-life of about 2 minutes before enzymes called DPP-4 break it down. That short window is exactly the design constraint that made the drug class hard to build.

GLP-1 works on at least four organs:

1. Pancreas. It tells beta cells to release insulin in response to a rising blood-glucose level, and it tells alpha cells to suppress glucagon. The result is better post-meal blood sugar control.
2. Stomach. It slows gastric emptying, so food stays in the stomach longer. This blunts the post-meal glucose spike and creates a longer-lasting sense of fullness.
3. Brain. It acts on the hypothalamus and the brainstem to reduce appetite and food cravings. Several studies show GLP-1 reduces the reward value of food at a neurological level.
4. Heart and kidneys. Receptors exist in cardiovascular and renal tissue. Recent trials suggest GLP-1 medications reduce major adverse cardiac events independent of weight loss.

The reason GLP-1 medications work for both diabetes and obesity is that the same hormone is involved in both conditions. People with type 2 diabetes have blunted GLP-1 responses to meals. People with obesity often have reduced satiety signaling. A long-acting GLP-1 analog corrects both problems at once.

The discovery: from Gila monster venom to a $50 billion drug class

The drug class started with a lizard. In 1990, an endocrinologist named John Eng discovered that the venom of the Gila monster contained a peptide called exendin-4. The reptile only eats a few times a year, and exendin-4 helped its body manage blood sugar across long fasting windows. Exendin-4 turned out to be a near-perfect long-acting GLP-1 analog.

Exenatide, the synthetic version of exendin-4, became the first FDA-approved GLP-1 drug in 2005. It required twice-daily injections. The next generation (liraglutide, approved 2010) lasted 24 hours. Semaglutide (approved 2017) lasted a week. Tirzepatide (approved 2022) added the GIP receptor for additional metabolic effect.

Each generation got more durable, more potent, and more convenient. The current generation (semaglutide, tirzepatide) is what most patients picture when they hear "GLP-1."

How GLP-1 medications differ from the natural hormone

The native GLP-1 your gut releases lasts about 2 minutes. A GLP-1 medication is an engineered version designed to resist DPP-4 enzyme breakdown and bind more tightly to the GLP-1 receptor. The result is a single injection that delivers the hormone's effect for a week or longer.

Three engineering tricks make this possible:

• Amino acid substitutions. Replacing a single amino acid at position 8 (alanine to glycine in liraglutide; alanine to aminoisobutyric acid in semaglutide) blocks DPP-4 cleavage.
• Fatty acid attachment. A long fatty acid chain attached to the peptide makes it bind to albumin, the most abundant protein in blood. Albumin acts as a slow-release reservoir.
• Sequence extensions. Some agents add extra amino acids that don't change receptor binding but slow renal clearance.

A native GLP-1 burst after a meal is a small, fast signal. A weekly injection of semaglutide is a large, sustained signal. The body experiences GLP-1 the way it would after a much bigger meal, all the time. That's why appetite drops, gastric emptying slows, and weight comes down.

The full list of GLP-1 drugs on the market

Tirzepatide is technically a "dual agonist" rather than a pure GLP-1 drug, but it's commonly grouped with GLP-1s because the GLP-1 receptor is one of its two targets. Most newer obesity medications in the pipeline (retatrutide, orforglipron, survodutide) are dual or triple agonists building on the same approach.

What GLP-1 medications treat (and what they don't)

FDA-approved indications:

• Type 2 diabetes. Reduces A1C by 1 to 2 percentage points on average. Lowers cardiovascular events. First-line therapy for many newly diagnosed patients.
• Obesity (BMI 30+, or BMI 27+ with a comorbidity). Wegovy, Saxenda, and Zepbound are the approved options. Average weight loss is 15 to 22% at maintenance dose for tirzepatide; 12 to 15% for semaglutide.
• Obstructive sleep apnea (Zepbound, 2024 approval). Tirzepatide reduced apnea-hypopnea index by about 50% in the SURMOUNT-OSA trial.
• Cardiovascular risk reduction in obese adults (Wegovy). The SELECT trial showed a 20% reduction in major cardiac events.

Off-label or investigational uses:

• Polycystic ovary syndrome (PCOS): improves insulin resistance and sometimes restores ovulation
• Non-alcoholic fatty liver disease (NAFLD): reduces liver fat and inflammation
• Alcohol use disorder: ongoing trials show reduced cravings
• Parkinson's disease: small trials suggest possible neuroprotective effect

What GLP-1 doesn't do:

• It doesn't cure type 1 diabetes (insulin production by beta cells must exist for the drug to work)
• It doesn't replace insulin in patients who already need insulin therapy
• It doesn't burn fat directly; weight loss comes from reduced food intake driven by appetite suppression
• It doesn't work permanently after stopping; weight regain is the rule, not the exception

The clinical data: how much weight, how much A1C

The numbers come from large randomized trials. These are the headline results most providers reference.

Tirzepatide for obesity (SURMOUNT-1, Jastreboff et al., NEJM 2022, N=2,539, 72 weeks):

Semaglutide for obesity (STEP 1, Wilding et al., NEJM 2021, N=1,961, 68 weeks):

Tirzepatide for type 2 diabetes (SURPASS-2, Frias et al., NEJM 2021, N=1,879, 40 weeks):

The results are consistent across trials: more potent agents and higher doses produce larger effects, with plateaus around 20 to 22% weight loss for the most potent dual-agonist medications.

Side effects and the mechanism behind them

Most GLP-1 side effects come from the same mechanism that makes the drug work: slowed gastric emptying and altered gut signaling.

Common (10 to 50% of patients during titration):

• Nausea, especially in the first 8 weeks
• Constipation or diarrhea
• Fullness after small meals (this is the desired effect, but feels uncomfortable)
• Fatigue, especially during early weeks
• Mild headache
• Reduced taste enjoyment for fatty or sugary foods

Uncommon (1 to 5%):

• Vomiting requiring dose reduction
• Gallstones during rapid weight loss
• Acid reflux
• Hair shedding (telogen effluvium from rapid caloric deficit)
• Dehydration

Rare but serious (less than 1%):

• Pancreatitis (about 0.3% per year of use)
• Severe gastroparesis
• Acute kidney injury, usually secondary to severe vomiting
• Allergic reactions
• Possible thyroid C-cell tumors (rodent finding; human signal unclear)

Most side effects improve with slow dose escalation, anti-nausea support, and dietary changes. About 5 to 10% of patients discontinue any GLP-1 due to intolerable side effects.

Who shouldn't take a GLP-1

GLP-1 medications are contraindicated or relatively contraindicated in:

• Personal or family history of medullary thyroid carcinoma (MTC). Black-box warning; rodent data showed C-cell tumors at high doses.
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Same reason as above.
• Active pancreatitis or recent pancreatitis history. Increased risk of recurrence.
• Severe gastroparesis. Slowing the stomach further can cause severe symptoms.
• Pregnancy or actively trying to conceive. Animal studies show fetal harm; stop at least 2 months before trying.
• Type 1 diabetes. No proven benefit and theoretical risk of DKA from reduced caloric intake.
• Severe gastrointestinal disease, severe inflammatory bowel disease, or recent bowel surgery.

A licensed clinician reviews these before prescribing. Many digital-health intake forms ask about each contraindication directly.

Compounded vs brand-name GLP-1: a real comparison

Compounded semaglutide and tirzepatide are prepared by state-licensed compounding pharmacies in response to individual prescriptions. They contain the same active ingredient as the brand-name drugs but are not FDA-approved.

Compounded GLP-1:

• Lower cost (roughly $179 to $399 per month vs $940 to $1,400 for brand)
• Drawn from a vial with a U-100 insulin syringe
• May contain additives like vitamin B12 or B-complex
• Available even when brand-name supply is constrained
• Not FDA-approved; not interchangeable with brand-name

Brand-name GLP-1:

• FDA-approved with full clinical trial support
• Pre-filled pen device
• Consistent dosing without measurement error
• Higher cost, often requiring insurance to be affordable
• Brand-specific savings cards for eligible patients

The decision is patient-specific. Patients with strong insurance coverage often choose brand-name. Patients paying cash or whose plan denies coverage often choose compounded. A licensed clinician should walk through the trade-offs.

What happens when you stop

The honest answer: most patients regain a meaningful portion of lost weight after stopping a GLP-1.

The STEP-4 extension trial (Rubino et al., JAMA 2021) followed semaglutide patients who stopped after 20 weeks. By week 68 (48 weeks off the drug), they had regained about two-thirds of the weight they had lost. The patients who stayed on semaglutide kept losing weight.

The SURMOUNT-4 trial showed similar results for tirzepatide: stopping the medication after a year led to regain of 14% of body weight over the next 12 months, while continuing led to additional 5% loss.

The interpretation is straightforward. GLP-1 medications work by suppressing appetite and slowing the stomach. When the drug is gone, both effects fade within a few weeks. Hunger returns to baseline. The behaviors that built obesity in the first place tend to return unless the patient has used the medication window to build new habits.

For most patients, GLP-1 is a long-term treatment, similar to medication for high blood pressure or high cholesterol. Tapering and discontinuation should be a planned, supervised process if attempted.

FAQ

What does GLP-1 stand for? GLP-1 stands for glucagon-like peptide-1. It's a 30-amino-acid hormone released by L-cells in the small intestine after eating. The name comes from its structural similarity to glucagon, although its effects on blood sugar are opposite.

Is GLP-1 a hormone or a drug? Both. GLP-1 is naturally a hormone produced by your gut. GLP-1 medications are engineered drugs that mimic the hormone's effect but last much longer. When people say "I'm on a GLP-1," they usually mean the medication.

What's the difference between GLP-1 and GIP? Both are incretin hormones. GLP-1 mainly suppresses appetite and slows gastric emptying. GIP affects fat metabolism and may amplify GLP-1's effects when both receptors are activated together. Tirzepatide activates both; semaglutide activates only GLP-1.

Are GLP-1 medications safe long-term? The longest published data follows patients for 4 to 6 years on continuous semaglutide therapy. The safety profile remained consistent. Pancreatitis rates are slightly elevated above background. Cardiovascular outcomes appear protective. Long-term thyroid risk remains theoretical based on rodent data.

Can I get GLP-1 for weight loss without diabetes? Yes. Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide) are FDA-approved specifically for weight loss in adults with BMI 30+ or BMI 27+ with a weight-related comorbidity. Saxenda (liraglutide 3.0 mg) is also approved for obesity.

How fast does GLP-1 work? Appetite suppression often shows within the first week. Measurable weight loss usually appears by week 4. Maximum weight loss occurs around month 12 to 18 at maintenance dose. A1C reduction in diabetes patients is meaningful by week 4 and reaches steady state by week 12.

Do GLP-1 medications cause muscle loss? Some lean mass loss occurs with any rapid weight loss, including GLP-1 therapy. About 25 to 40% of total weight lost is lean mass on average. Resistance training and adequate protein intake (1.2 to 1.6 g/kg/day) reduce lean mass loss meaningfully.

Can I drink alcohol on a GLP-1? You can, but tolerance is often reduced. Many patients report feeling intoxicated faster and developing a much smaller alcohol appetite overall. The combination of GLP-1 and alcohol can also worsen nausea. There's no direct drug interaction with moderate use.

Why is my appetite so suppressed on GLP-1? GLP-1 medications act on the hypothalamus and brainstem to reduce hunger signals, slow gastric emptying so you feel full faster and longer, and reduce the reward value of food. Most patients describe a "quieting" of food thoughts within the first few weeks.

Do GLP-1 medications cause depression? Published trial data has not shown an increased rate of depression. The FDA and EMA reviewed post-market data in 2024 and found no causal link. Some patients report mood changes that may relate to caloric deficit or rapid weight loss rather than the drug itself. Tell your provider about any new mood symptoms.

Can I take GLP-1 if I have a thyroid nodule? A simple thyroid nodule (not medullary thyroid cancer) is not an absolute contraindication. Patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 should not take GLP-1 medications. A clinician should review thyroid imaging before prescribing if there's any concern.

Will my insurance cover GLP-1 for weight loss? Coverage varies. Many commercial plans cover Wegovy or Zepbound for obesity if BMI criteria are met and prior authorization is approved. Most state Medicaid programs do not cover GLP-1 for weight loss. Medicare Part D recently expanded coverage for Wegovy when prescribed for cardiovascular risk reduction, not weight loss alone.

What's the cheapest way to get a GLP-1? For diabetes patients with commercial insurance, the manufacturer copay savings cards (Novo Nordisk for Ozempic, Lilly for Mounjaro) can reduce copays to $25 per fill. For uninsured patients, compounded semaglutide or tirzepatide through a licensed telehealth platform is typically the most affordable option, starting around $179 per month.

Author / review note

Reviewed by the FormBlends Medical Team. References include Drucker (Cell Metabolism, 2018) on GLP-1 physiology, Jastreboff et al. (New England Journal of Medicine, 2022) for SURMOUNT-1, Wilding et al. (New England Journal of Medicine, 2021) for STEP 1, Frias et al. (New England Journal of Medicine, 2021) for SURPASS-2, Rubino et al. (JAMA, 2021) for STEP-4, Lincoff et al. (New England Journal of Medicine, 2023) for SELECT, and the FDA prescribing information for each agent.

Sources

1. Drucker (Cell Metabolism, 2018) on GLP-1 physiology.
2. Jastreboff et al. (New England Journal of Medicine, 2022) for SURMOUNT-1.
3. Wilding et al. (New England Journal of Medicine, 2021) for STEP 1.
4. Frias et al. (New England Journal of Medicine, 2021) for SURPASS-2.
5. Rubino et al. (JAMA, 2021) for STEP-4.
6. Lincoff et al. (New England Journal of Medicine, 2023) for SELECT.
7. The FDA prescribing information for each agent.

Footer disclaimers (all 4 verbatim)

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Rybelsus, Saxenda, and Victoza are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Trulicity is a registered trademark of Eli Lilly and Company. Byetta and Bydureon are registered trademarks of AstraZeneca. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.